Appeal No. 2005-1511
Application No. 09/879,398
Falkenburg discloses the use of allogeneic bone marrow transplantation
(BMT) for the treatment of leukemias, including acute lymphoblastic leukemia
(ALL), in order to increase the likelihood of a graft-versus-leukemia (GVL)
response in the patient. See, e.g., the abstract and p. 306, col. 1, first complete
para. Falkenburg further discloses that since the use of T cell-depleted BMTs
“reduce[s] the incidence and severity of graft-versus-host disease (GVHD)[,]” but
increases the risk of relapse, “GVL reactivity has been attributed to the T
lymphocytes from the graft.” Id., the abstract. Falkenburg still further discloses
that “leukemia-reactive cytotoxic T-lymphocyte (CTL) lines and clones could be
generated from the peripheral blood of HLA-genotypically identical siblings of
patients with leukemia by stimulation of the donor cells with irradiated leukemic
cells from the patients.” Id., the abstract; see also, p. 306, col. 2, para. 1.
Falkenburg still further discloses using irradiated leukemic cells from patients
who relapsed after receiving an allogeneic HLA-identical BMT for three types of
leukemias, including ALL, to stimulate the patient’s own CTL lines to reduce the
risk of GvHD. Id., the abstract; p. 306, col. 2, last para.; p. 307, col. 1, first
complete para. According to Falkenburg this latter procedure produces
antileukemic cell lines which “will be used in a phase I/II trial for the treatment of
relapsed leukemia after allogeneic BMT.” Id., p. 308, col. 2, last sentence.
Coligan discloses a method for the negative selection of T cells from
peripheral blood mononuclear cells using immunomagnetic microspheres coated
with CD4+ and CD8+ antibodies.
9
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Next
Last modified: November 3, 2007